Omega-3 Prescription Drugs Market size is estimated at USD 1.5 billion in 2024 and is expected to exceed USD 4 billion by the end of 2037, expanding at over 8% CAGR during the forecast period i.e., between 2025-2037. In 2025, the industry size of omega-3 prescription drugs is assessed at USD 1.6 billion.
The omega-3 prescription drugs market has grown significantly based on increasing awareness about health benefits attributed to these fatty acids, associated particularly with the prevention of cardiovascular diseases. Fundamentally, active ingredients such as EPA and DHA reduce triglyceride levels effectively and are highly in demand for reducing heart diseases. Thus, prescription drugs such as Vascepa and Lovaza are becoming popular in the healthcare industry. Better drug formulations and access to improved healthcare services have created significant opportunities for manufacturers in this sector.
Several governments worldwide now recognize the significant contribution that omega-3 can make to improving public health and are actively advocating research and healthcare reforms to extend their reach and visibility. As omega-3 supplements are presumed to provide health benefits, especially in the prevention of heart diseases and stroke, their use has gained popularity, with the Centers for Disease Control and Prevention (CDC) estimating that American adults, 5.4% of age group 20 to 39, 12.5% of age group 40 to 59, currently use omega-3 supplements. This represents a growing trend in preventive healthcare and heightened interest in proactive health management by consumers.
Growth Drivers:
Challenges:
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
8% |
|
Base Year Market Size (2024) |
USD 1.5 billion |
|
Forecast Year Market Size (2037) |
USD 4 billion |
|
Regional Scope |
|
Drug Type (Vascepa, Lovaza)
The vascepa segment is anticipated to hold a revenue share of around 47.7% in the omega-3 prescription drugs market during the forecast period. Such a dominating position is mainly due to its already established preference to reduce cardiovascular risks among patients suffering from high levels of triglycerides. Vascepa is uniquely formulated based on highly purified EPA and has been approved by the FDA, extending its applicability in the prevention of heart disease. In August 2023, Amarin Corporation and Neopharm collaborated to make an exclusivity agreement for the commercialization of VAZKEPA in Israel, continuing to further strengthen the company's leading position in international markets. Such developments are anticipated to boost the segment’s growth over the forecast period.
Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
By 2037, retail pharmacy segment is expected to hold more than 52.3% omega-3 prescription drugs market share. This is due to the increasing convenience and accessibility of prescription drugs from retail settings. Preference for over-the-counter solutions among the patients is one of the major distribution dynamics that drives the omega-3 products. This is also being driven by the increasing adoption of e-prescriptions and telehealth services. In October 2022, the European Commission approved plant-based omega-3 products from DSM, enabling its wider dissemination across retail pharmacies within the EU. Such approvals are likely to drive the sales of omega-3 prescription drugs in retail pharmacies during the forecast period.
Our in-depth analysis of the omega-3 prescription drugs Market includes the following segments:
|
Drug Type |
|
|
Application |
|
|
Distribution Channel |
|
North America Market Analysis
North America is anticipated to lead the omega-3 prescription drugs market, holding a share of 45.6% during the forecast period. Some of the major factors driving the growth of the market include the increasing incidence of cardiovascular diseases and the strong presence of leading pharmaceutical companies. Besides this, rising consumer awareness related to heart health is one of the key factors highly influencing the demand for omega-3 prescription drugs in the region.
The U.S. dominates the market in North America due to its modern healthcare infrastructure and significant research and development related to omega-3 drugs. In March 2023, Hikma Pharmaceuticals launched Icosapent Ethyl Capsules in the U.S., further strengthening the favorable growth trends of the market. The higher the number of adoptions of omega-3 prescription drugs for cardiovascular risk reduction, the better the opportunity becomes for manufacturers in the sector.
Prescription omega-3 drugs are also finding increased demand in Canada in a national healthcare effort to combat heart disease. Increasing healthcare spending and a favorable government outlook toward parity in prevention are brightening the prospects for the omega-3 prescription drugs market. The various health programs of the government identify the key role omega-3 supplements play in maintaining long-term heart health.
Asia Pacific Market Analysis
Asia Pacific in omega-3 prescription drugs market is estimated to capture over 25% revenue share by 2037, driven by growing awareness among consumers and rising incidences of heart diseases. Moreover, attractive government policies toward preventive healthcare in the region is creating avenues for omega-3 drug producers. The growth in the middle-class population and increase in disposable income also surged demand for high-quality health supplements, including omega-3 products. In addition, stronger local pharmaceutical manufacturing is expected to improve the prospects of growth of both domestic and international participants in Asia Pacific.
India has emerged as a key omega-3 prescription drugs market in the Asia Pacific, fueled by growing awareness of preventive health. Various governmental healthcare-related initiatives have also stimulated the consumption of omega-3 supplements. Coromega launched its Pup Packets for pets in India in July 2021, whereby the innovation continued to meet not only human but also animal health care. This, along with the increasing demand for omega-3 supplements in various clinical applications for the management of heart diseases, has positioned India as one of the leading countries in the Asia Pacific.
The omega-3 prescription drugs market in China is expanding rapidly, fueled by growing awareness with respect to cardiovascular health and huge government support for improvement in healthcare. In February 2023, NMPA approved Vascepa from Amarin for a new drug application and opened the route for the launch of the drug in China. The approval is thus likely to have a big impetus on market growth during the forecast years.
The omega-3 prescription drugs market remains fiercely competitive among key players such as Amarin Corporation, Hikma Pharmaceuticals, Nordic Naturals, and DSM. These firms are emphasizing product innovation, strategic collaborations, and further expansion of their global reach. Vascepa by Amarin is among the popular products in the market, especially in cardiovascular health, whereas Hikma and Nordic Naturals continue expanding their product offerings within related markets. For example, In March 2023, Hikma Pharmaceuticals launched Icosapent Ethyl Capsules in the U.S., expanding its omega-3 prescription drugs portfolio. This is indicative of growing consciousness toward the prevention of cardiovascular diseases and exemplifies increasing competition amongst key players in the industry.
Here are some leading players in the omega-3 prescription drugs market:
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?